Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...
Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs
China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on...
AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...
Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...
Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...
Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...
Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...
Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...
Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million
Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...
Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...
Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...
Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment
Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...